Top

Published in:

Open Access 01-12-2018 | Research

FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

Published in: Radiation Oncology | Issue 1/2018

Abstract

Background

Concomitant chemo-radiotherapy is the reference treatment for non-resectable locally-advanced Non-Small Cell Lung Cancer (NSCLC). Increasing radiotherapy total dose in the whole tumour volume has been shown to be deleterious. Functional imaging with positron emission tomography (PET/CT) offers the potential to identify smaller and biologically meaningful target volumes that could be irradiated with larger doses without compromising Organs At Risk (OAR) tolerance. This study investigated four scenarios, based on ¹⁸FDG and ¹⁸F-miso PET/CT, to delineate the target volumes and derive radiotherapy plans delivering up to 74Gy.

Method

Twenty-one NSCLC patients, selected from a prospective phase II trial, had ¹⁸FDG- and ¹⁸F-miso PET/CT before the start of radiotherapy and ¹⁸FDG PET/CT during the radiotherapy (42Gy). The plans were based planned on a standard plan delivering 66 Gy (plan 1) and on three different boost strategies to deliver 74Gy total dose in pre-treatment ¹⁸FDG hotspot (70% of SUV_max) (plan 2), pre-treatment ¹⁸F-miso target (SUV_max > 1.4) (plan 3) and per-treatment ¹⁸FDG residual (40% of SUV_max). (plan 4).

Results

The mean target volumes were 4.8 cc (± 1.1) for ¹⁸FDG hotspot, 38.9 cc (± 14.5) for ¹⁸F-miso and 36.0 cc (± 10.1) for per-treatment ¹⁸FDG. In standard plan (66 Gy), the mean dose covering 95% of the PTV (D95%) were 66.5 (± 0.33), 66.1 (± 0.32) and 66.1 (± 0.32) Gy for ¹⁸FDG hotspot, ¹⁸F-miso and per-treatment ¹⁸FDG. In scenario 2, the mean D95% was 72.5 (± 0.25) Gy in ¹⁸FDG hotspot versus 67.9 (± 0.49) and 67.9 Gy (± 0.52) in ¹⁸F-miso and per-treatment ¹⁸FDG, respectively. In scenario 3, the mean D95% was 72.2 (± 0.27) Gy to ¹⁸F-miso versus 70.4 (± 0.74) and 69.5Gy (± 0.74) for ¹⁸FDG hotspot and per-treatment ¹⁸FDG, respectively. In scenario 4, the mean D95% was 73.1 (± 0.3) Gy to ¹⁸FDG per-treatment versus 71.9 (± 0.61) and 69.8 (± 0.61) Gy for ¹⁸FDG hotspot and ¹⁸F-miso, respectively. The dose/volume constraints to OARs were matched in all scenarios.

Conclusion

Escalated doses can be selectively planned in NSCLC target volumes delineated on ¹⁸FDG and ¹⁸F-miso PET/CT functional images. The most relevant strategy should be investigated in clinical trials.

Trial registration

(RTEP5, NCT01576796, registered 15 june 2012)

Arriagada R, Le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard JY, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys. 1991;20(6):1183–90.CrossRef

Wang YC, Tseng HL, Lin YH, Kao CH, Huang WC, Huang TC. Improvement of internal tumor volumes of non-small cell lung cancer patients for radiation treatment planning using interpolated average CT in PET/CT. PLoS One. 2013;8(5):e64665.CrossRef

Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.CrossRef

Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, et al. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014;4(5):342–8.CrossRef

Machtay M, Paulus R, Moughan J, Komaki R, Bradley JE, Choy H, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol. 2012;7(4):716–22.CrossRef

Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46(2):253–60.PubMed

Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, et al. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study). J Nucl Med. 2017;58(7):1045–53.CrossRef

Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, et al. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. J Nucl Med. 2013;54(9):1543–50.CrossRef

Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48(4):1015–24.CrossRef

10.

Chapet O, Kong FM, Quint LE, Chang AC, Ten Haken RK, Eisbruch A, et al. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys. 2005;63(1):170–8.CrossRef

11.

Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, et al. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. J Nucl Med. 2015;56(2):196–203.CrossRef

12.

Aerts HJ, Bussink J, Oyen WJ, van Elmpt W, Folgering AM, Emans D, et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer. 2012;75(1):73–6.CrossRef

13.

Calais J, Dubray B, Nkhali L, Thureau S, Lemarignier C, Modzelewski R, et al. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):858–67.CrossRef

14.

Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, Chan K, Zanzonico PB, Greco C, Ling CC, Humm JL, Schöder H. Fluorine-18-labeled Fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck Cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2010. https://doi.org/10.1016/j.ijrobp.2007.06.039 21.CrossRef

15.

Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC, Humm J. Prospective trial incorporating pre-/mid-treatment [18 F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):101–8.CrossRef

16.

Mees G, Dierckx R, Vangestel C, Laukens D, Van Damme N, Van de Wiele C. Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake? Mol Imaging. 2013;12(1):49–58.PubMed

17.

van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43(9):1392–8.CrossRef

18.

Liao ZX, Lee JJ, Komaki R, Gomez DR, O'Reilly M, Allen P, et al. Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. J Clin Oncol. 2016;34(15 suppl):8500.CrossRef

19.

J F, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J, McGarry RC. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2013;85(5):1325–31.CrossRef

Title: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer
Publication date: 01-12-2018
Published in: Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-018-1147-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

Abstract

Background

Method

Results

Conclusion

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?

Changes in cardiac volume determined with repeated enhanced 4DCT during chemoradiotherapy for esophageal cancer

Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study

Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT

Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease

Investigating rectal toxicity associated dosimetric features with deformable accumulated rectal surface dose maps for cervical cancer radiotherapy